EFTA
Search
Search
Entities
About
Settings
/
to search
Search
Search syntax help
Dataset
Set 1
Set 2
Set 3
Set 4
Set 5
Set 6
Set 7
Set 8
Set 9
Set 10
Set 11
Set 12
Sort
Relevance
Most pages
Most words
Dataset
Newest
Oldest
Status
All
Extracted
Failed
DOJ Status
All
Removed
Available
Date Range
Undated only
–
Page Count
–
Saved Searches
+
2 results for “
"Dabrafcnib"
”
Export
EFTA02714314
Set 11
3p
850w
pill. Last January 2014, the FDA approved the first combined inhibitor drug for melanoma:
Dabrafcnib
and Trametinib, designed to block certain BRAF enzyme pathway mutations and resistant mutations. In July
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02714314.pdf
EFTA01936162
Keyboard Shortcuts
/
Focus search
Esc
Blur input
O
Open PDF
←
→
Paginate
Set 10
2p
396w
predominance and tumor level. The inhibitor cocktail that was approved by the FDA is
Dabrafcnib
and trametinib, designed to block certain BRAF enzyme pathway genetic mutations. These mutations occur
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01936162.pdf
Corpus: 1990-03-17 – 2025-12-01
←
December 2025
→
Mo
Tu
We
Th
Fr
Sa
Su
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Undated
(150,429)
None
Light
Medium
Heavy
Results by Dataset
2 total
Set 10
1
Set 11
1